Chimerix, Inc. Appoints Kenneth I. Moch Chief Operati... ( RESEARCH TRIANGLE P...)

Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer

Date:7/16/2009

RESEARCH TRIANGLE PARK, N.C., July 16 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.

Mr. Moch brings more than 25 years of experience in managing and financing biomedical technologies, and has played a key role in building several life science companies. In this newly-created position, Mr. Moch will be responsible for overseeing corporate and financial strategy, business development and operations, reporting to George Painter, Ph.D., Chimerix's President and Chief Executive Officer.

"Ken is a seasoned industry executive whose depth and breadth of leadership experience significantly strengthens the Chimerix management team," said Dr. Painter. "I look forward to working closely with Ken on a shared vision for advancing Chimerix's pipeline of potent broad spectrum antiviral compounds, and building an organization focused on advancing important new medicines."

"With a rich pipeline of next-generation antiviral drug candidates, productive platform technology, an extraordinary library of new leads and supportive top-tier investors, Chimerix combines deep assets with the scientific heritage necessary to emerge at the forefront of antiviral drug development," said Mr. Moch. "I am excited to join this veteran team. We have the opportunity to create much-needed new pharmaceutical products with promise in a broad range of challenging viral diseases."

Prior to joining Chimerix, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services to life sciences companies, where he most recently served as President and CEO of BioMedical Enterprises, Inc., a developer and marketer of orthopaedic memory metal implants. Previously, he was Managing Director, Healthcare Investment
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Progenitor Cell Therapy Appoints VP of Manufacturing Operations
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
4. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
5. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
6. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
7. Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry
8. Novavax Appoints Stanley Erck to Board of Directors
9. Qforma Appoints Four Executives in Sales and Field Operations
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services

Post Your Comments:

Chimerix, Inc. Appoints Kenneth I. Moch Chief Operati...( RESEARCH TRIANGLE P...)